Brief: Reviva Announces Positive Full Dataset For 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine In Schizophrenia
02/06/2025 13:27
June 2 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O: REVIVA ANNOUNCES POSITIVE FULL DATASET FOR 1-YEAR PHASE 3 RECOVER OPEN LABEL EXTENSION STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA Source text: ID:nGNXFBP4J Further company coverage: RVPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture